1 Steps
Maximum: 1 CME cr.
Sign in to view your progression
Programme Background
Learning Objectives
Target Audience
Accreditation Information
Disclosures/Disclaimers

The advent of newer immunotherapeutic and molecularly targeted agents has provided a number of effective options for cancer treatment. Despite the remarkable clinical efficacy of these agents in a number of malignancies, evidence shows that they are not sufficiently active for many patients. There is a potential to further enhance the clinical benefits of monotherapies by combining agents with synergistic mechanisms of action.

The rationale for combining regimens is to provide the durable clinical benefit of immunotherapy along with the rapid and high response rates produced by molecularly targeted therapy. This approach potentially offers both short- and long-term benefits to patients. By combining strategies, we take advantage of distinct but complementary mechanisms of action for such agents.

The increasingly complex treatment landscape for RCC poses a challenge for urologists. In managing advanced RCC, they need to keep up with new data on all treatment options, select therapies on an individual case basis, and use the optimal sequence or combinations while effectively managing side effects. Therefore, there is an opportunity to create awareness regarding ongoing trials that can provide clarity regarding patient selection and treatment decisions.

Upon completion of this educational activity, the participant should be able to:

- Review clinical data on established and emerging therapies for patients with advanced RCC
- Assess the latest efficacy and safety data on the combined use of immune checkpoint inhibitors and targeted therapies and the clinical implications of these findings
- Discuss the importance of personalizing treatment using knowledge of patient biomarkers and the most recent clinical evidence
- Evaluate when to choose the combined immunotherapy + targeted therapy approach
- Optimize therapy based on patient characteristics and prior treatment history

This program is designed for urologists, medical oncologists, radiation oncologists, residents, and fellows who have an interest in immunotherapy and systemic treatments for kidney cancer around the world who are SIU members or SIU Academy-registered members.

This program is accredited by the European Accreditation Council for Continuing Medical Education (EACCME).

The credits for the users of the module will be 1 European CME credit (ECMEC®) for every hour (60 minutes of actual e-learning excluding introductions etc.) of use, provided that the users have completed a module and have passed the relevant assessment.

CHAIR

Thomas Powles, MBBS, MRCP, MD
London, United Kingdom
Disclosures: Roche, Genetech, Merck, Pfizer, Novartis, Bristol-Myers Sqibb (BMS), AstraZeneca (AZ)


SCIENTIFIC COMMITTEE MEMBERS

Jürgen Gschwend, MD, PhD
Munich, Germany
Disclosures: Bayer, BMS, Janssen, MSD, Novartis, Pierre Fabre, Pfizer, Roche

Laurence Albiges, MD, PhD
Paris, France
Disclosures: Pfizer, Novartis, Bristol-Myers Squibb (BMS), IPSEN, Peloton Therapeutics, Roche, MS

The Evolution of Treatment for RCC: Is Combination Immunotherapy-Targeted Therapy the New Standard?

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies